Unicycive Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
UNCY Nasdaq 2830 unicycive.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Unicycive Therapeutics, Inc.

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Jul 1st, 2026 4:13 pm
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Jun 30th, 2026 3:34 pm
Sector Update: Healthcare Stocks Softer Late Afternoon - Jun 30th, 2026 1:41 pm
Top Midday Decliners - Jun 30th, 2026 12:41 pm
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Jun 30th, 2026 8:10 am
Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) - Jun 30th, 2026 6:42 am
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA) - Jun 30th, 2026 5:05 am
Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - May 14th, 2026 5:19 pm
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 5:05 am
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Apr 9th, 2026 5:05 am
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - Mar 30th, 2026 5:05 am
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - Feb 4th, 2026 5:05 am
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - Jan 29th, 2026 7:15 am
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - Jan 29th, 2026 5:05 am
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - Dec 29th, 2025 5:05 am
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Dec 29th, 2025 5:02 am
Unicycive Therapeutics to Participate in Upcoming Investor Events in December - Nov 25th, 2025 5:05 am
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well - Nov 18th, 2025 4:09 am
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 12th, 2025 5:05 am
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Nov 3rd, 2025 5:05 am